In Brief: LaserSight Inc.
This article was originally published in The Gray Sheet
Executive Summary
LaserSight Inc.: Commences Phase IIb U.S. clinical trials of its PhotoScan 2000 excimer laser for photorefractive keratectomy (PRK). The 125-patient, five-site study includes patients with up to -10 diopters of nearsightedness, LaserSight says. Phase III trials of the PRK device are ongoing in Canada and Europe. The firm also is conducting Phase II trials in the U.S., Canada and Europe for photoastigmatic refractive keratectomy (PARK), designed to correct "myopic astigmatism up to 6.5 diopters in conjunction with the correction of myopia of up to -10.5 diopters"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.